Baird raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $115 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which increased confidence in the second half of the year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target raised to $113 from $104 at Raymond James
- Zimmer Biomet price target raised to $96 from $91 at UBS
- Zimmer Biomet Holdings: Balancing Strong Segment Growth with US Knee Challenges – Hold Rating Maintained
- Cautious Outlook and Hold Recommendation for Zimmer Biomet Holdings Amid Volatility Concerns
- Zimmer Biomet Reports Strong Q2 2025 Results